Cookson Peirce & Co. Inc. Takes $317,000 Position in Sangamo Therapeutics, Inc. (SGMO)
Cookson Peirce & Co. Inc. acquired a new stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 35,990 shares of the biopharmaceutical company’s stock, valued at approximately $317,000. Cookson Peirce & Co. Inc. owned 0.05% of Sangamo Therapeutics at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Highbridge Capital Management LLC acquired a new position in Sangamo Therapeutics in the first quarter valued at about $496,000. Swiss National Bank lifted its position in Sangamo Therapeutics by 26.4% in the second quarter. Swiss National Bank now owns 143,560 shares of the biopharmaceutical company’s stock valued at $1,263,000 after buying an additional 30,000 shares during the last quarter. Wells Fargo & Company MN lifted its position in Sangamo Therapeutics by 13.0% in the first quarter. Wells Fargo & Company MN now owns 295,770 shares of the biopharmaceutical company’s stock valued at $1,538,000 after buying an additional 34,128 shares during the last quarter. RA Capital Management LLC acquired a new position in Sangamo Therapeutics in the second quarter valued at about $11,000,000. Finally, United Services Automobile Association acquired a new position in Sangamo Therapeutics in the first quarter valued at about $1,394,000. 63.43% of the stock is owned by hedge funds and other institutional investors.
Shares of Sangamo Therapeutics, Inc. (NASDAQ SGMO) traded up 0.168% during mid-day trading on Tuesday, hitting $14.875. 325,768 shares of the stock traded hands. The company’s market cap is $1.24 billion. The stock has a 50 day moving average price of $14.37 and a 200-day moving average price of $9.22. Sangamo Therapeutics, Inc. has a one year low of $2.65 and a one year high of $17.06.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.06. Sangamo Therapeutics had a negative return on equity of 38.49% and a negative net margin of 246.39%. The business had revenue of $8.30 million during the quarter, compared to analysts’ expectations of $5.82 million. During the same quarter in the previous year, the business earned ($0.38) EPS. The company’s revenue for the quarter was up 124.3% on a year-over-year basis. On average, analysts forecast that Sangamo Therapeutics, Inc. will post ($0.82) earnings per share for the current fiscal year.
In other news, Director William R. Ringo sold 31,000 shares of the business’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $14.37, for a total transaction of $445,470.00. Following the completion of the sale, the director now owns 31,800 shares in the company, valued at approximately $456,966. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Curt A. Herberts III sold 11,474 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $10.44, for a total value of $119,788.56. Following the sale, the vice president now owns 23,991 shares of the company’s stock, valued at approximately $250,466.04. The disclosure for this sale can be found here. Insiders have sold a total of 72,474 shares of company stock valued at $1,019,009 in the last quarter. Company insiders own 5.50% of the company’s stock.
SGMO has been the topic of a number of recent analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $17.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, June 22nd. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Friday, August 18th. ValuEngine raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Piper Jaffray Companies set a $8.00 target price on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research report on Thursday, August 10th. Finally, BidaskClub cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $14.40.
Sangamo Therapeutics Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.